tiprankstipranks

Monopar Therapeutics reports Q2 EPS (10c), consensus (9c)

Cash, cash equivalents and short-term investments as of June 30, 2024, were $7.1M. Monopar projects that its current funds will be sufficient to continue operations at least through August 31, 2025.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue